Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb;115(1):21-39.
doi: 10.1080/20477724.2020.1845005. Epub 2020 Nov 14.

Zika virus pathogenesis and current therapeutic advances

Affiliations
Review

Zika virus pathogenesis and current therapeutic advances

Caroline Mwaliko et al. Pathog Glob Health. 2021 Feb.

Abstract

Zika virus (ZIKV) is an emerging arthropod-borne flavivirus that, upon infection, results in teratogenic effects and neurological disorders. ZIKV infections pose serious global public health concerns, prompting scientists to increase research on antivirals and vaccines against the virus. These efforts are still ongoing as the pathogenesis and immune evasion mechanisms of ZIKV have not yet been fully elaborated. Currently, no specific vaccines or drugs have been approved for ZIKV; however, some are undergoing clinical trials. Notably, several strategies have been used to develop antivirals, including drugs that target viral and host proteins. Additionally, drug repurposing is preferred since it is less costly and takes less time than other strategies because the drugs used have already been approved for human use. Likewise, different platforms have been evaluated for the design of vaccines, including DNA, mRNA, peptide, protein, viral vectors, virus-like particles (VLPSs), inactivated-virus, and live-attenuated virus vaccines. These vaccines have been shown to induce specific humoral and cellular immune responses and reduce viremia and viral RNA both in vitro and in vivo. Importantly, most of these vaccines have entered clinical trials. Understanding the viral disease mechanism will provide better strategies for developing therapeutic agents against ZIKV. This review provides a comprehensive summary of the viral pathogenesis of ZIKV and current advancements in the development of vaccines and drugs against this virus.

Keywords: Antivirals; pathogenesis; sfRNAs; therapeutics; vaccines; zika virus.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the authors.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
The biology of ZIKV, showing the transmission modes, tropism, and disease symptoms associated with ZIKV
Figure 2.
Figure 2.
Subgenomic flaviviral RNA location and its roles in pathogenesis. (a) ZIKV genome scheme showing the location of sfRNA at the 3ʹUTR. (b) sfRNA pathogenic functions in arthropod and vector hosts. (a) and (b) are reproduced with permission and minor modifications from Slonchak and Khromykn [78]

Similar articles

Cited by

References

    1. Nyaruaba R, Mwaliko C, Mwau M, et al. Arboviruses in the East African Community partner states: a review of medically important mosquito-borne Arboviruses. Pathog Glob Health. 2019;113:209–228. - PMC - PubMed
    1. Dick GWA, Kitchen SF, Haddow AJ, et al. Isolations and serological specificity. Trans R Soc Trop Med Hyg. 1952;46. DOI: 10.1016/0035-9203(52)90042-4. - DOI - PubMed
    1. MacNamara FN. Zika virus: A report on three cases of human infection during an epidemic of jaundice in Nigeria. Trans R Soc Trop Med Hyg. 1954;48:139–145. - PubMed
    1. Lupton K. Zika virus disease: a public health emergency of international concern. Br J Nurs. 2016;25:198–202. - PubMed
    1. Lanciotti RS, Lambert AJ, Holodniy M, et al. Phylogeny of Zika Virus in Western Hemisphere, 2015. Emerg Infect Dis. 2016;22:933–935. - PMC - PubMed